Thesis (doctoral)--München, 1982.

Techn. Hochsch., Diss., 2002--Aachen.

L’alpha-foetoprotéine (AFP) est la protéine majoritaire du sérum fœtal de mammifère. C’est une glycoprotéine produite et sécrétée par l’endoderme viscéral du sac vitellin, les hépatocytes fœtaux et dans une moindre mesure, par l’intestin fœtal. Son profil d’expression est onco-fœtal : la synthèse de cette protéine chute fortement après la naissance mais peut reprendre en cas de régénération hépatique ou en cas de tumeurs diverses. Cette protéine est capable de fixer les oestrogènes et jouerait un rôle dans la différenciation sexuelle du cerveau femelle. Deux invalidations du gène de l’AFP ont été réalisées au Laboratoire de Biologie du Développement afin de comprendre la fonction de cette protéine. Dans les deux cas, des souris homozygotes pour l’allèle invalidé (souris AFP KO) ont été obtenues. Elles sont viables et apparemment phénotypiquement normales, mais les femelles sont stériles, suite à une anovulation. Il a été démontré que l’absence d’ovulation provient d’un mauvais fonctionnement de l’axe hypothalamo-hypopysaire. Nous avons démontré au cours de cette thèse que l’ARN messager d’une série de gènes était sous-représenté au sein de l’hypophyse des souris femelles invalidées pour le gène Afp. Nous trouvons parmi ces gènes, ceux d’une cascade particulièrement importante pour l’ovulation, la cascade du récepteur de la GnRH. La fertilité des souris femelles AFP KO, ainsi que le taux d’expression des gènes testés dans l’hypophyse, sont restaurés si ces souris se développent dans un environnement appauvri en oestrogènes. Nous avons donc pu corriger le phénotype des souris femelles invalidées pour le gène de l’AFP. Nous avons en ce faisant démontré que l’AFP, par sa capacité de fixer les oestrogènes, protégeait le cerveau femelle en développement des effets masculinisants de ces hormones

In der vorliegenden Arbeit wurden die Krankengeschichten von 93 Patienten mit sekundären Lebertumoren kolorektaler Karzinome und von 39 Patienten mit Hepatozellulären Karzinomen aufgearbeitet, die im Zeitraum 1995 bis 2003 an der Chirurgischen Universitätsklinik Würzburg in kurativer Absicht operiert wurden. Es konnte eine umfassende Darstellung der epidemiologischen Daten, der Tumorstadien sowie der operativen und postoperativen Verläufe erreicht werden. Als prognostisch ungünstige Faktoren für das Langzeitüberleben der Patienten mit Lebermetastasen kolorektaler Karzinome konnten ein CEA-Wert von mehr als 16,8 ng/ml und ein Sicherheitsabstand von weniger als 5 mm identifiziert werden. Kein Zusammenhang fand sich mit dem Diagnosezeitpunkt der Metastasierung, der Art der Resektion und dem Alter der Patienten. Ebenfalls konnte kein statistisch signifikanter Zusammenhang zwischen Staging, Grading und Lokalisation des Primärtumors nachgewiesen werden. Bei den Patienten mit Hepatozellulären Karzinomen wurden das Alter, der Zirrhosegrad der Leber, die Größe des Tumors und die Höhe des Tumormarkers AFP als signifikante Faktoren für das Langzeitüberleben gefunden. Die Art der Resektion zeigt eine deutliche Tendenz zur Signifikanz und scheint ebenfalls einen Einfluss auf das Outcome der Patienten zu haben. Insgesamt konnte nachgewiesen werden, dass die Leberresektion primärer und sekundärer Lebertumoren ein sicheres Operationsverfahren mit niedriger Morbidität und Mortalität ist, das das Überleben der Patienten signifikant verlängert. Offen bleibt, wie sich die Therapie des hepatozellulären Karzinoms vor dem Hintergrund der Lebertransplantation weiterentwickeln wird. Zum einen stellt die Transplantation ein Verfahren dar, bei dem höhere Überlebenszeiten und längere tumorfreie Intervalle erreicht werden können, zum anderen ist der bestehende Mangel an Spendeorganen momentan das größte Problem, um jedem Patienten, der ein Kandidat zur Transplantation wäre, ein Organ zur Verfügung zu stellen. / In this study, 93 patients with secondary liver tumors of colorektal cancer and of 39 patients with hepatocellular carcinoma were analyzed, who underwent operation between 1995 and 2003 in the "Chirurgische Universitätsklink Würzburg". Epidemiological data, tumor stages and intraoperative and postoperative processes are described in this study. A CEA level of more than 16,8 ng/ml and a safety margin of less than 5 mm were identified as prognostically unfavorable factors for long time survival for patients with liver metastases of colorektal cancer. Time of diagnosis, resection technique and the patients age did not correlate with survival. Staging, grading and localisation of the primary tumor did not correlate either. Age, grade of cirrhosis, size of tumor and AFP-level of patients with hepatocellular carcinoma were determined as significant factors for long term survival. The resection technique showed an obvious tendency to significance and seemed to have an influence on patients outcome. In summary this study proved, that liver resection of primary and secondary liver tumors is a safe procedure with low morbidity and mortality, that significantly prolongs patients survival. However the therapy of hepatocellular carcinoma including liver transplantation remains to be focused on. On the one hand transplantation is a procedure that prolongs patientssurvival and reaches longer tumor free intervalls. On the other hand the lack of organs is the biggest problem to offer every candidate an organ.

Statement of problem: We have shown that the C677T 5,10 methylenetetrahydrofolate reductase (MTHFR) variant is associated with elevated maternal serum α-fetoprotein (MSAFP), the most common screening test for neural tube defects (NTD). Therefore, past contradictory studies of NTDs and C677T MTHFR may have been biased because of changes in case populations after prenatal diagnosis and termination of pregnancy. Further, an unexplained elevation of MSAFP is known to increase the risk for later pregnancy complications. Is the C677T MTHFR variant a predisposing genetic variant for both NTDs and later complications of pregnancy? Methods: A retrospective study of women with pregnancies resulting in NTD outcome and women with unexplained elevations of MSAFP was undertaken. Women and their partners were genotyped for the C677T MTHFR allele. Couples with a pregnancy resulting in a NTD outcome were compared to couples whose pregnancy outcome did not involve. Couples with unexplained elevations of MSAFP who did and did not have later complications of pregnancy were also compared. Allele frequencies for all groups were then compared against the previously established Manitoba population allele frequency (based on 977 consecutive newborn metabolic screening bloodspots). A review of all studies of NTDs and association with the C677T MTHFR variant was undertaken to determine if the association between the variant and MSAFP is a source of bias. NTD incidence was examined before and after folic acid food fortification introduced in Canada in 1999. Results: There is an increase in the allele frequency of the C677T MTHFR variant in parents with an unexplained elevated MSAFP followed by later complications of pregnancy. The C677T MTHFR variant is also a contributing genetic factor to NTDs worldwide. The incidence of NTDs in Manitoba has decreased by 37% since food fortification with folic acid was introduced. Conclusions: The C677T MTHFR variant is a contributing genetic factor to both later complications of pregnancy after an unexplained elevation of MSAFP and to NTDs. This variant is folate sensitive and folic acid fortification has reduced the incidence of NTDs. / February 2005

Statement of problem: We have shown that the C677T 5,10 methylenetetrahydrofolate reductase (MTHFR) variant is associated with elevated maternal serum α-fetoprotein (MSAFP), the most common screening test for neural tube defects (NTD). Therefore, past contradictory studies of NTDs and C677T MTHFR may have been biased because of changes in case populations after prenatal diagnosis and termination of pregnancy. Further, an unexplained elevation of MSAFP is known to increase the risk for later pregnancy complications. Is the C677T MTHFR variant a predisposing genetic variant for both NTDs and later complications of pregnancy? Methods: A retrospective study of women with pregnancies resulting in NTD outcome and women with unexplained elevations of MSAFP was undertaken. Women and their partners were genotyped for the C677T MTHFR allele. Couples with a pregnancy resulting in a NTD outcome were compared to couples whose pregnancy outcome did not involve. Couples with unexplained elevations of MSAFP who did and did not have later complications of pregnancy were also compared. Allele frequencies for all groups were then compared against the previously established Manitoba population allele frequency (based on 977 consecutive newborn metabolic screening bloodspots). A review of all studies of NTDs and association with the C677T MTHFR variant was undertaken to determine if the association between the variant and MSAFP is a source of bias. NTD incidence was examined before and after folic acid food fortification introduced in Canada in 1999. Results: There is an increase in the allele frequency of the C677T MTHFR variant in parents with an unexplained elevated MSAFP followed by later complications of pregnancy. The C677T MTHFR variant is also a contributing genetic factor to NTDs worldwide. The incidence of NTDs in Manitoba has decreased by 37% since food fortification with folic acid was introduced. Conclusions: The C677T MTHFR variant is a contributing genetic factor to both later complications of pregnancy after an unexplained elevation of MSAFP and to NTDs. This variant is folate sensitive and folic acid fortification has reduced the incidence of NTDs.

Statement of problem: We have shown that the C677T 5,10 methylenetetrahydrofolate reductase (MTHFR) variant is associated with elevated maternal serum α-fetoprotein (MSAFP), the most common screening test for neural tube defects (NTD). Therefore, past contradictory studies of NTDs and C677T MTHFR may have been biased because of changes in case populations after prenatal diagnosis and termination of pregnancy. Further, an unexplained elevation of MSAFP is known to increase the risk for later pregnancy complications. Is the C677T MTHFR variant a predisposing genetic variant for both NTDs and later complications of pregnancy? Methods: A retrospective study of women with pregnancies resulting in NTD outcome and women with unexplained elevations of MSAFP was undertaken. Women and their partners were genotyped for the C677T MTHFR allele. Couples with a pregnancy resulting in a NTD outcome were compared to couples whose pregnancy outcome did not involve. Couples with unexplained elevations of MSAFP who did and did not have later complications of pregnancy were also compared. Allele frequencies for all groups were then compared against the previously established Manitoba population allele frequency (based on 977 consecutive newborn metabolic screening bloodspots). A review of all studies of NTDs and association with the C677T MTHFR variant was undertaken to determine if the association between the variant and MSAFP is a source of bias. NTD incidence was examined before and after folic acid food fortification introduced in Canada in 1999. Results: There is an increase in the allele frequency of the C677T MTHFR variant in parents with an unexplained elevated MSAFP followed by later complications of pregnancy. The C677T MTHFR variant is also a contributing genetic factor to NTDs worldwide. The incidence of NTDs in Manitoba has decreased by 37% since food fortification with folic acid was introduced. Conclusions: The C677T MTHFR variant is a contributing genetic factor to both later complications of pregnancy after an unexplained elevation of MSAFP and to NTDs. This variant is folate sensitive and folic acid fortification has reduced the incidence of NTDs.

No description available.

Une même hormone peut exercer des effets différents sur le développement des caractéristiques de type femelle selon la période à laquelle elle est produite : lstradiol nous a ainsi dévoilé son double jeu, révélant à la fois des effets déféminisants prénataux pouvant sexercer jusqu5ème jour postnatal et des effets féminisants sexerçant dès le 15ème jour postnatal. / A steroid hormone can have different effects on female characteristics development according to the period it is produced : estradiol has defeminizing effects on brain development until postnatal day 5, and feminizing effects from postnatal day 15.

Several cancers are associated with abnormal serum concentrations of tumor markers such as prostate specific antigen (PSA) in prostate tumor diseases, alfa-fetoprotein (AFP) or human chorionic gonadotrophin (hCG) in germ cell tumors or persistent gestational trophoblastic diseases (GTD). Cancer treatment should induce decline of serum tumor marker concentrations. The predictive values of many kinetic parameters supposed to characterize tumor marker declines such as nadir, time-point cutoff, half-life, time to normalization etc..., have been reported in previous studies. However very few of them have been used in routine due to the lack of outcome reproducibility. Population pharmacokinetic approach-based modeling is already used in pharmacokinetic studies. It might be helpful to characterize tumor marker decline equations dynamically and overcome limitations of previous studies. The feasibility and the relevance of this approach were assessed in 4 studies involving: PSA titers in patients with prostate adenoma or cancer treated with surgery; hCG-AFP in non-seminomatous germ cell tumor patients treated with BEP regimen (Bleomycin-Etoposide-Cisplatin) and hCG in GTD patients treated with methotrexate. Tumor marker decline modeling was feasible in all studies provided the methodology was adjusted to marker specificities. Apparent clearance of hCG and PSA might enable identification of patients with unfavorable decline profiles and thereby with high risk of relapse. Confirmatory studies with independent cohorts of patients are warranted